Peregrine Ventures

Peregrine Ventures is an Israeli life-sciences fund with a particular strength in medical devices, digital health, and pharma and therapeutics, and a structural advantage that is unusual in the region: it can support companies from pre-seed incubation all the way through pre-IPO growth rounds. For physician founders building hardware-heavy or regulated products, the lifecycle coverage matters because it removes one of the most difficult financing transitions in medtech.

The thesis is rooted in medical hardware and digital health, with therapeutics rounding out the book. Peregrine is comfortable with the long timelines and capital intensity of regulated devices, and the firm has built operating muscle around clinical trials, regulatory strategy, and reimbursement pathways. Digital health investments tend to be the kind that integrate with hospital systems or clinical workflows rather than direct-to-consumer wellness plays. The fund does not publish a granular portfolio breakdown, but the operating pattern is consistent across categories.

Check sizes sit in the 5 million to 25 million dollar range, with the firm leading or co-leading rounds and following on through subsequent stages. Stage coverage runs from seed through growth, with an attached incubation capability for the earliest companies. Geography is Israel-anchored, with a clear expectation that companies will commercialize globally and particularly in the United States. The fund engages with United States hospital systems and reimbursement consultants as part of portfolio support.

The team is built around partners with deep healthcare operating histories, and Peregrine engages hands-on with portfolio companies on regulatory and commercial strategy. The incubation arm provides additional structure for the earliest-stage companies, which is useful for clinician-founders making the transition from practice to startup.

Approach Peregrine when you are a physician founder building a medical device, a regulated digital health product, or a therapeutics platform with a clear clinical thesis. Pure consumer-wellness or unregulated software plays are a poor fit. The most reliable path in is a warm introduction from Israeli medtech operators, United States health-system executives, or other life-sciences VCs who have co-invested with Peregrine. Time the conversation when you have a regulatory pathway clarified, a clinical evidence plan, and a credible team. Pre-seed founders can engage through the incubation function, but they should expect the diligence bar to reflect the serious capital that follows. Peregrine is built for founders who want a long-term partner through the regulatory and commercial slog.